
|Articles|March 8, 2010
- September 2009
- Volume 3
- Issue 9
Studies from Around the Globe
Author(s)Onclive Team
Key Takeaways
- Personalized treatment strategies have advanced the management of lung cancer brain metastases, integrating targeted therapies and immunotherapies for improved outcomes.
- Stereotactic radiosurgery and whole-brain radiotherapy are evolving with new systemic therapies, maintaining their importance in treatment plans.
Advertisement
Articles in this issue
almost 16 years ago
Abraxis BioScience Hopes to 'Nab' a Bigger Share of the Taxanes Marketalmost 16 years ago
By the Numbers: If the US Health Care System Had Only 100 Physiciansalmost 16 years ago
In the News Briefsalmost 16 years ago
IASLC's 13th World Conference on Lung CancerAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5




































